Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Skin Cancer01:30

Skin Cancer

5.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

4.8K
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simulated daylight versus conventional PDT for mild to moderate actinic keratoses: A randomized controlled trial.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Assessment of high- and low-risk histopathologic subtypes of basal cell carcinoma using artificial intelligence and dermatologist evaluation.

JAAD international·2026
Same author

Changes in insight and outcome over the early course of first-episode psychosis. The OPTiMiSE trial.

Schizophrenia research. Cognition·2026
Same author

Child and adolescent psychiatry: challenges, solutions, opportunities, and future directions.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2026
Same author

Perspectives on Artificial Intelligence in Dermatology: An International Cross-Sectional Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Mapping policies related to problematic usage of the internet in seven European countries: Netherlands, Spain, Hungary, Lithuania, Portugal, Estonia and Switzerland.

Comprehensive psychiatry·2026

Related Experiment Video

Updated: Apr 22, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

7.9K

Classic Kaposi's sarcoma treated with topical rapamycin.

Blanca Díaz-Ley1, Emiliano Grillo, Luis Ríos-Buceta

  • 1Department of Dermatology, Ramon y Cajal University Hospital, University of Alcalá, Madrid, Spain.

Dermatologic Therapy
|October 15, 2014
PubMed
Summary

Topical rapamycin effectively healed Kaposi's sarcoma (KS) lesions in an immunocompetent patient. This topical application of rapamycin offers a potential new treatment for KS.

Keywords:
Kaposi's sarcomarapamycintreatment

More Related Videos

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

12.1K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

850

Related Experiment Videos

Last Updated: Apr 22, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

7.9K
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

12.1K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

850

Area of Science:

  • Oncology
  • Virology
  • Dermatology

Background:

  • Kaposi's sarcoma (KS) is an angioproliferative disorder linked to human herpesvirus 8 (HHV-8).
  • Research focuses on HHV-8 genes, particularly viral G protein-coupled receptor (vGPCR), for KS pathogenesis.
  • vGPCR's oncogenic potential is associated with activating the mammalian target of rapamycin (mTOR) pathway.

Observation:

  • An immunocompetent patient with Kaposi's sarcoma lesions was treated with topical rapamycin.
  • The treatment involved a 16-week course of topical rapamycin application.

Findings:

  • The patient achieved complete clinical and histologic healing of KS lesions.
  • Topical rapamycin demonstrated significant efficacy in treating KS.

Implications:

  • Topical rapamycin represents a potential novel therapeutic strategy for Kaposi's sarcoma.
  • This approach may offer a new treatment option for KS patients, particularly those seeking localized therapy.